JPWO2022087339A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022087339A5 JPWO2022087339A5 JP2023524629A JP2023524629A JPWO2022087339A5 JP WO2022087339 A5 JPWO2022087339 A5 JP WO2022087339A5 JP 2023524629 A JP2023524629 A JP 2023524629A JP 2023524629 A JP2023524629 A JP 2023524629A JP WO2022087339 A5 JPWO2022087339 A5 JP WO2022087339A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- patient
- dose
- complement
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105018P | 2020-10-23 | 2020-10-23 | |
| US63/105,018 | 2020-10-23 | ||
| PCT/US2021/056153 WO2022087339A1 (en) | 2020-10-23 | 2021-10-22 | Methods of treating patients having complement disorders using anti-c5 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023548046A JP2023548046A (ja) | 2023-11-15 |
| JPWO2022087339A5 true JPWO2022087339A5 (https=) | 2024-10-29 |
| JP2023548046A5 JP2023548046A5 (https=) | 2024-10-29 |
Family
ID=78695818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524629A Pending JP2023548046A (ja) | 2020-10-23 | 2021-10-22 | 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240018220A1 (https=) |
| EP (1) | EP4232473A1 (https=) |
| JP (1) | JP2023548046A (https=) |
| CA (1) | CA3196434A1 (https=) |
| WO (1) | WO2022087339A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| CA3080187A1 (en) | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| US12404320B2 (en) | 2018-05-31 | 2025-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| ES2984352T3 (es) | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
| IL307593A (en) * | 2017-01-31 | 2023-12-01 | Chugai Pharmaceutical Co Ltd | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
| CA3080187A1 (en) * | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| MA51147A (fr) * | 2017-12-13 | 2021-03-24 | Regeneron Pharma | Associations d'anticorps anti-c5 et utilisations associées |
-
2021
- 2021-10-22 CA CA3196434A patent/CA3196434A1/en active Pending
- 2021-10-22 US US18/032,959 patent/US20240018220A1/en active Pending
- 2021-10-22 JP JP2023524629A patent/JP2023548046A/ja active Pending
- 2021-10-22 EP EP21810811.6A patent/EP4232473A1/en active Pending
- 2021-10-22 WO PCT/US2021/056153 patent/WO2022087339A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7227312B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 | |
| JP7101621B2 (ja) | 単一ドメイン血清アルブミン結合タンパク質 | |
| TWI660972B (zh) | 抗ｍｃａｍ抗體及相關使用方法 | |
| TWI673287B (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| JP2018501813A5 (https=) | ||
| JP7461875B2 (ja) | 病気の症状の治療又は予防に使用するための抗アドレノメデュリン（ａｄｍ）バインダー | |
| JP2020536097A5 (https=) | ||
| US9816999B2 (en) | Neo antibodies for diagnostic imaging of tissue injury | |
| TWI869542B (zh) | 抗ＦｃＲｎ抗體、其抗原結合片段及其醫藥用途 | |
| TWI836070B (zh) | 抗trop-2抗體、其抗原結合片段及其醫藥用途 | |
| JP2023548046A (ja) | 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 | |
| JP2026057572A (ja) | Ｃ５関連疾患の治療または予防のための投与レジメン | |
| JPWO2022087339A5 (https=) | ||
| EP4393949A1 (en) | Pharmaceutical composition containing fusion protein | |
| JP6143209B1 (ja) | 自己免疫疾患用または難治性血管炎用の治療剤、および、これらの疾患の診断のためのデータの取得方法 | |
| WO2024245388A1 (zh) | 抗pvrig抗体及其应用 | |
| HK40036076A (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof | |
| EP4583910A1 (en) | Supplemental dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) | |
| WO2025108438A1 (zh) | 抗her3抗体药物偶联物和抗vegf抗体治疗肿瘤的方法 | |
| TW202547857A (zh) | 抗ｈａｓ抗體及其組合物 | |
| HK40036076B (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof | |
| JPWO2019183448A5 (https=) |